Instruction for use: Naproxen

Active substance Naproxen

ATX code M01AE02 Naproxen

Pharmacological group

NSAIDs - Propionic acid derivatives

Nosological classification (ICD-10)

M06.9 Other specified rheumatoid arthritis

Rheumatoid arthritis,Pain syndrome in rheumatic diseases, Pain in rheumatoid arthritis, Inflammation in rheumatoid arthritis, Degenerative forms of rheumatoid arthritis, Children's rheumatoid arthritis, Exacerbation of rheumatoid arthritis, Acute articular rheumatism, Rheumatic arthritis, Rheumatic polyarthritis, Rheumatoid arthritis, Rheumatic polyarthritis, Rheumatoid arthritis, Rheumatoid arthritis of active course, Rheumatoid arthritis, Rheumatoid polyarthritis, Acute rheumatoid arthritis, Acute rheumatism

M10 Gout

Exacerbation of gout, Acute articular attack with gout, Acute gouty attack, Gouty attack, Recurrent gout attacks, Chronic gout

M15-M19 Osteoarthritis

M45 Ankylosing spondylitis

Ankylosing spondylarthrosis, Marie-Strumpel disease, Ankylosing spondylitis, Pain syndrome in acute inflammatory diseases of the musculoskeletal system, Pain syndrome in chronic inflammatory diseases of the musculoskeletal system, Bechterew's disease, Ankylosing spondylitis, Diseases of the spinal column, Rheumatic spondylitis, Bechterew-Marie-Strumpel disease

M77.9 Other unspecified

Capsule, Periarthritis, Tendonitis, Tendopathy, Periarthropathy

M79.0 Other unspecified rheumatism

Degenerative rheumatic disease, Degenerative and rheumatic diseases of the tendons, Degenerative rheumatic diseases, Localized forms of rheumatism of soft tissues, Rheumatism, Rheumatism with a pronounced allergic component, Rheumatism of the articular and extraarticular, Rheumatic attack, Rheumatic complaints, Rheumatic diseases, Rheumatic disease of the spine, Relapses of rheumatism, Articular and extra-articular rheumatism, Articular and muscular rheumatism, Articular rheumatism, Articular syndrome with rheumatism, Chronic rheumatic pain, Chronic articular rheumatism, Rheumatoid diseases, Rheumatic diseases of the intervertebral disc

N94.6 Dysmenorrhea Unspecified

Pain during menstruation, Functional disorders of the menstrual cycle, Menstrual cramps, Emmeniopathy, Pain during menstruation, Painful menstrual irregularities, algomenorrhea, algomenoreya, Pain smooth muscle spasm, Pain spasm of smooth muscles (renal and biliary colic, intestinal spasms, dysmenorrhea), Pain spasm of smooth muscles of internal organs (kidney and biliary colic, intestinal spasms, dysmenorrhea), Disalgomenoreya, dysmenorrhea, Dysmenorrhea (essential) (Exfoliative), menstrual disorder, menstruation painful, metrorrhagia, Violation of the menstrual cycle, Menstrual irregularities, Prolaktinzavisimoe menstrual disorders, Prolaktinzavisimoe menstrual dysfunction, Pain spasm of smooth muscles of internal organs, Spasmodic dysmenorrhea, Primary disalgomenoreya

R50 Fever of unknown origin

Malignant hyperthermia, Hyperthermia malignant

T14.9 Injury unspecified

Pain syndrome after trauma, Pain syndrome with injuries, Pain syndrome with trauma and after surgery, Pain in case of injury, Pain of a traumatic nature, Joint pain with injuries, Postoperative and post-traumatic pain, Pain in case of injury, Pain of a traumatic origin, Severe pain syndrome of traumatic origin, Deep tissue damage, Deep scratches on the trunk, Closed injury, Minor Household Injuries, Minor skin damage, Violations of the integrity of soft tissues, Uncomplicated trauma, Extensive traumatic injury, Acute pain syndrome of traumatic origin, Edema with trauma, Postponed sports injuries, Post-traumatic pain, Soft tissue injuries, Joint wounds, Sports injuries, Injury, Traumatic pain, Traumatic pains, Traumatic infiltrate,Injuries to sports

Composition and form of release

1 tablet contains naproxen 250 or 500 mg; in bottles of dark glass of 50 pcs., in a box 1 vial or in a blister 10 pcs., in a box 5 blisters (250 mg), or in a blister 10 pcs., in a box 2 blisters (500 mg).

pharmachologic effect

Pharmacological action - anti-inflammatory, antipyretic, analgesic.

It inhibits cyclooxygenase and blocks the synthesis of PG. Prevents the aggregation of platelets.

Pharmacokinetics

Quickly and almost completely absorbed from the digestive tract. Almost completely (99%) binds to proteins. The volume of distribution is 0.09 l / kg. The cavity of the joint penetrates slowly: 3-4 hours after ingestion, the concentration in the synovial fluid is 50% of the plasma level, and after 15 hours - about 74%. A significant therapeutic effect develops after 10 hours. More than half of the administered amount undergoes biotransformation - forms glucuronides. It is excreted in the urine, about 10% unchanged, 60% - in the glucuronated. T1 / 2 - 12-15 hours. With hepatic and renal failure, excretion can be significantly reduced.

Indication

Articular syndrome with rheumatism, rheumatoid arthritis, periarthritis, ankylosing spondylitis, osteoarthrosis, gout, trauma and inflammatory diseases of the musculoskeletal system and soft tissues, primary dysmenorrhea, febrile condition with infectious and inflammatory diseases.

Contraindications

Hypersensitivity, peptic ulcer of the stomach and duodenum in the period of exacerbation, hemorrhagic diathesis, bronchospasm attacks associated with taking an NSAID in anamnesis, pregnancy, breast-feeding.

Application in pregnancy and lactation

Contraindicated.

Side effects

Heartburn, nausea, epigastric pain, constipation or diarrhea, vomiting, headache, impaired concentration, depression, disorientation, visual impairment, hemorrhages, skin-allergic reactions.

Dosing and Administration

Inside, with food. Adults: at the beginning of treatment and in acute conditions - 500-1000 mg / day in 2 divided doses (morning and evening); maintenance dose - 500 mg / day in 1 or 2 doses. Acute attack of gout - 750 mg in 1 dose, then 250-500 mg every 8 hours for 2-3 days.

Children: 10 mg / kg / day in 2 divided doses every 12 hours.

Precautionary measures

Before and during treatment (especially long) it is necessary to regularly examine the function of the kidneys. It should be borne in mind that naproxen increases the time of bleeding.

storage Conditions

In a dry place protected from light.

Keep out of the reach of children.

Shelf life

3 years.

Do not use after the expiry date printed on the package.